GLP-1 medication like Wegovy and Zepbound have been racking up gross sales and new indications, as researchers study extra about how the medication have an effect on the physique past simply weight reduction.
However one of many extra anticipated research exploring how they influence Alzheimer’s illness has discovered no significant impact, Novo Nordisk stated in a press launch on Nov. 24
The corporate, which makes semaglutide (bought as Wegovy for weight reduction and Ozempic for diabetes), stated that its drug didn’t present any extra profit over placebo in two trials of individuals with early Alzheimer’s. The corporate is planning to launch extra information at a presentation on the Medical Trials on Alzheimer’s Illness convention in early December and on the Alzheimer’s and Parkinson’s Illnesses conferences in March 2026.
The 2-year examine included greater than 3,800 folks with gentle cognitive impairment or gentle dementia on account of Alzheimer’s, half of whom have been randomly assigned to take a semaglutide capsule every single day, and half of whom took placebo. The corporate stated that folks receiving the drug did present enhancements in sure organic measures of Alzheimer’s illness, however that these modifications didn’t translate into slower illness development as measured by an ordinary check of a number of areas of cognitive potential, together with reminiscence, downside fixing, sociability, and self-care. Consultants are ready for extra detailed information on the outcomes to grasp whether or not the enhancements in markers of the illness may very well be early indicators of potential profit, particularly if mixed with different methods like conduct modifications and at the moment accessible drugs.
Learn Extra: The Heavy Value of Utilizing Weight-Loss Medication to Get Skinny
Researchers have been hopeful that the weight-loss medication would possibly have an effect on Alzheimer’s, since irritation contributes to the neurodegenerative illness and the medication appear to have an anti-inflammatory impact. Research in animal fashions, in addition to observational research of individuals taking the drug to deal with diabetes or weight achieve, hinted that the drug could sluggish the advance of Alzheimer’s.
New Alzheimer’s therapies are wanted, since at the moment solely two—lecanemab (from Eisai) and donanemab (from Lilly)—deal with the foundation causes of Alzheimer’s. Each work by attacking the buildup of amyloid plaques within the mind and might sluggish illness development by as much as 30% for folks with mild-to-moderate illness. “These outcomes will assist us refine our understanding of this class of medication,” stated Maria Carrillo, chief science officer and medical affairs lead for the Alzheimer’s Affiliation, in a assertion. “Although this semaglutide capsule didn’t assist towards Alzheimer’s, the sphere will proceed to research this class of medication, as they might act otherwise.”
Eli Lilly, which makes the opposite drug within the class, tirzepatide, has not stated whether or not it plans to check its product’s impact on Alzheimer’s.
Novo Nordisk stated it could discontinue a deliberate one-year observe up of the folks within the trials.
Discussion about this post